SCHEMBL3038064

SCHEMBL3038064

COCCO[C@H]1CC[C@H](N2C(=O)c3ccccc3C2=O)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
TSHR P16473 4/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ACHE P22303 1/20 0.38
PDK2 Q15119 1/20 0.36
CHRM2 P08172 1/20 0.36
OPRM1 P35372 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
IKZF3 Q9UKT9 1/20 0.36
CYP1A2 P05177 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CD38 P28907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038067 1.00 L3MBTL1 (0.51) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL600925 0.87 L3MBTL1 (0.56) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL600924 0.87 L3MBTL1 (0.56) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL601653 0.85 L3MBTL1 (0.59) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL8069723 0.85 L3MBTL1 (0.59) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL601652 0.85 L3MBTL1 (0.59) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL20337367 0.84 L3MBTL1 (0.53) L3MBTL1TSHRKMT2AALDH1A1MAPK1
SCHEMBL14010107 0.82 L3MBTL1 (0.47) L3MBTL1TSHRKMT2ALMNAGAA
SCHEMBL5009463 0.82 L3MBTL1 (0.47) L3MBTL1TSHRKMT2ALMNAGAA
SCHEMBL5009462 0.82 L3MBTL1 (0.47) L3MBTL1TSHRKMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216798-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC (JP) 2010-08-26 US disclosed
WO-2008119721-A1 COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed
EP-1910369-A1 FUSED HETEROCYCLES AS LCK INHIBITORS Astellas Pharma Inc. (JP) 2008-04-16 EP disclosed
WO-2007013673-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216798-A1 FUSED HETEROCYCLES AS LCK INHIBITORS LCK, ZAP70, FYN L3MBTL1 918/4885TSHR 974/4885KMT2A 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.